Upon request, data are available from the Central Africa International Epidemiologic Database to Evaluate AIDS (CA-IeDEA) and the relevant Institutional Data Access / Ethics Committee of Burundi, Democratic Republic of Congo and Rwanda for researchers who meet the criteria for access to confidential data. All requests for data should be made to Donald Hoover (<donhoover@aol.com>) and Qiuhu Shi (<qshi@data2solutions.com>).

Introduction {#sec005}
============

At the end of 2015, an estimated 1.8 million \[1.5 million-2.0 million\] children less than 15 years of age were living with HIV worldwide, 90% in sub-Saharan Africa \[[@pone.0169871.ref001]\]. More than 90% of those children acquired their infection through mother-to-child transmission (MTCT) \[[@pone.0169871.ref001]\]. In the absence of ART, an estimated 26% of postnatally-infected and 52% of perinatally-infected children would die in the first year of HIV infection \[[@pone.0169871.ref002]\]. Poor immunological, growth, and neurodevelopmental outcomes are common in children who initiate ART at later stages of the disease \[[@pone.0169871.ref003]--[@pone.0169871.ref008]\].

Access to ART has increased substantially in low- and middle-income countries, with the greatest increase occurring in sub-Saharan Africa: from 100,000 people receiving ART in 2003 to 9.1 million in 2013 \[[@pone.0169871.ref001]\]. Along with this expansion in ART coverage, the World Health Organization (WHO) explicitly recommends ART initiation in i) all HIV infected children 1--10 years old living with HIV at any CD4 cell count or ii) as a priority among all children \<2 years old and those with severe or advanced HIV clinical disease (WHO clinical stage 3 or 4) and individuals with CD4% \<25% (if \<5 years old) or CD4 count ≤350 cells/mm3 (if ≥5 years old), or iii) among all children \<1 year old living with HIV irrespective of CD4 cell count \[[@pone.0169871.ref009], [@pone.0169871.ref010]\]. The impacts of the recommended changes on improved testing coverage (e.g., PMTCT and identification of exposed infants), better infant diagnosis (e.g., PCR) and more importantly immediate initiation of ART among children in Central Africa has not been documented. Although the proportion of HIV-infected children receiving ART in sub-Saharan Africa lags behind that of adults (23% of children vs. 37% of adults in 2013) \[[@pone.0169871.ref001]\], this disparity is even greater in West and Central Africa, where just 13% of HIV-infected children vs. 32% of adults were receiving ART in 2013 \[[@pone.0169871.ref001]\].

Only a few published studies have examined temporal trends in the characteristics of children initiating ART in sub-Saharan Africa \[[@pone.0169871.ref011]--[@pone.0169871.ref015]\]. Although these studies showed a decline over time in disease severity at ART initiation, a substantial proportion of infants and children were still initiating ART at an advanced disease stage \[[@pone.0169871.ref011]--[@pone.0169871.ref013]\]. To improve timely HIV diagnosis and ART initiation, and to reduce morbidity and mortality among HIV-infected children in resource-constrained settings, it is important to understand the characteristics of children enrolling in care and initiating ART and how these have changed over time as provision of prevention of mother-to-child transmission (improved identification of HIV-exposed infants), early infant diagnosis and testing capacity (e.g., DNA PCR) improves, and HIV treatment guidelines expand in Central Africa. Knowledge of these characteristics will facilitate efforts to identify challenges with timely HIV diagnosis and ART initiation. We thus assessed temporal trends in the characteristics of HIV-infected children at enrollment in HIV care (a proxy for time of diagnosis) and at time of ART initiation from 2004 to 2013 in three Central African countries: Burundi, the Democratic Republic of Congo (DRC), and Rwanda.

Materials and Methods {#sec006}
=====================

Study setting and participants {#sec007}
------------------------------

We analyzed data on pediatric patients aged 0--15 years from Burundi, the DRC and Rwanda participating in the Central Africa International Epidemiologic Databases to Evaluate AIDS (CA-IeDEA). CA-IeDEA is a multi-country project that collects secondary data from patients receiving HIV care and treatment in the Central African region. The two clinics in the DRC, ten in Rwanda, and three in Burundi that contributed data have been previously described \[[@pone.0169871.ref016]--[@pone.0169871.ref018]\]. In each participating clinic, data were collected using standardized clinical paper forms that were regularly entered into electronic databases. HIV infection was generally diagnosed by serological testing in children older than 18 months and by virological testing in children younger than 18 months. Children confirmed as HIV-infected by serological or virological testing who were 0--15 years of age at HIV care enrollment between 2004 and 2013 were included in this analysis.

Variables and statistical analysis {#sec008}
----------------------------------

The main variables of interest were CD4 cell count, WHO clinical stage, age, and weight-for-age Z score (WAZ). CD4 count, WAZ and WHO clinical stage at enrollment into care were defined as the measurement taken at or closest to (not later than six months before or after) the enrollment date if no measures were taken on the date of enrollment. CD4 cell counts and WAZ at ART initiation were defined as the measurement taken at ART initiation (i.e. not earlier than 6 months before or later than 3 months after). WAZ was calculated using 2006 WHO standards \[[@pone.0169871.ref019]\] for children 10 years or younger and Centers for Disease Control and Prevention standards for children older than 10 years \[[@pone.0169871.ref020]\]. Other continuous variables were categorized as follows: CD4 count (\<200, 200--450, \>450 cells/μl), and age (0--24, 25--60, 61--84, 85--120, and 121--156 months). Year of enrollment and year of ART initiation were grouped as 2004--05, 2006--07, 2008--09, 2010--11, and 2012--13 to reflect temporal changes in WHO guidelines over time.

Demographic characteristics (age and sex) and HIV-associated characteristics (CD4 count, WHO stage, and WAZ score) at care enrollment and ART initiation were analyzed. Descriptive statistics (numbers and percentages for categorical variables, and median and interquartile range (IQR) for continuous variables) were calculated. Chi-square and Kruskal-Wallis tests were used to examine changes in distributions over the 10-year period.

Ethical approval for the study was granted by the Albert Einstein College of Medicine Institutional Review Board in New York, and by the relevant ethics review boards in Rwanda (National Health Research Committee and National Ethics Committee), Burundi (Comite National d' Ethique) and DRC (Ministère de l\'enseignement supérieur et universitaire, Université de Kinshasa École de santé publique). Data for the Central Africa International Epidemiologic Database to Evaluate AIDS (CA-IeDEA) is publicly available upon request as part of the global IeDEA consortium.

Results {#sec009}
=======

[Table 1](#pone.0169871.t001){ref-type="table"} shows characteristics of children when they enrolled into care (n = 3426) and at ART initiation (n = 2058). Overall, from 2004--13, the median age at enrollment was 58.2 months (interquartile range (IQR); 19.8, 102) and 70.3 (IQR; 29.2, 113) at ART initiation. Nearly equal proportions of boys and girls enrolled in care, and initiated ART over the 10-year period.

10.1371/journal.pone.0169871.t001

###### Characteristics of children at enrollment in care and at ART initiation in the Central Africa IeDEA Cohort, 2004--2013.

![](pone.0169871.t001){#pone.0169871.t001g}

                                         [Enrollment]{.ul}   [ART Initiation]{.ul}
  -------------------------------------- ------------------- -----------------------
  [**Age (months) (n, %)**]{.ul}                             
  Median (IQR)                           58.2 (19.8; 102)    70.3 (29.2; 113)
  0--24                                  982 (28.7)          422 (20.5)
  25--60                                 775 (22.6)          497 (24.1)
  61--84                                 489 (14.3)          267 (13.0)
  85--120                                626 (18.3)          439 (21.3)
  121--156                               554 (16.2)          433 (21.0)
  [**Sex (n, %)**]{.ul}                                      
  Male                                   1669 (48.7)         1047 (50.9)
  Female                                 1757 (51.3          1011 (49.1)
  [**Country (n, %)**]{.ul}                                  
  Burundi                                722 (21.1)          299 (14.5)
  DRC                                    1307 (38.1)         1002 (48.7)
  Rwanda                                 1397 (40.8)         757 (36.8)
  [**CD4 Count (n, %)**]{.ul}                                
  Median (IQR)                           648 (339; 1029)     457 (249; 936)
  \<200                                  309 (14.2)          325 (19.6)
  200--450                               429 (19.7)          493 (29.7)
  \>450                                  1440 (66.1)         842 (50.7)
  [**WHO Clinical Stage (n, %)**]{.ul}                       
  No Data                                1185 (34.6)         335 (16.3)
  I                                      611 (17.8)          310 (15.1)
  II                                     625 (18.2)          411 (20.0)
  III                                    901 (26.3)          903 (43.9)
  IV                                     104 (3.0)           99 (4.8)
  [**Weight-for-age Z-score**]{.ul}                          
  Median (IQR)                           -1.8 (-3.0;-0.7)    -1.9 (-3.0; -0.8)
  \>-2                                   1276 (55.1)         922 (52.9)
  -3 to -2                               455 (19.8)          377 (21.6)
  \<3                                    585 (25.3)          445 (25.5)
  [**Year (n, %)**]{.ul}                                     
  2004--05                               630 (18.4)          280 (13.6)
  2006--07                               680 (19.8)          431 (20.9)
  2008--09                               697 (20.3)          413 (20.1)
  2010--11                               729 (21.3)          468 (22.7)
  2012--13                               690 (20.1)          466 (22.6)

The median time from enrollment in care to ART initiation for the different age groups are: 1.3 for 0--24 and 25--60 months, 2.1 for 61--84 months, 3.1 for 85--120 months and 2.4 for 121--156 months. The median CD4 count was 648 cells/μl (IQR; 339, 1029) at enrollment into care and 457 cells/μl (IQR; 249, 936) at ART initiation. WHO clinical staging data were not available for more than one-third of children at care enrollment and for about 16% of children at ART initiation. Over one-third of children with WHO staging data were classified as stage III or IV when they enrolled into care, with nearly half (48%) of these classified as stage III or IV at ART initiation. Median WAZ was -1 (IQR; -3.0, -0.7) at care enrollment and -1 (IQR; -3.0, 0.8) at ART initiation. Overall, children ≤24 months of age were 29% of those enrolled in care and 21% of those initiated on ART.

[Table 2](#pone.0169871.t002){ref-type="table"} reports children's characteristics by year of enrollment into care. Median age at enrollment fell from 77.2 months in 2004--05 to 30.3 months in 2012--13 (p = \<0.0001). The proportion of children ≤24 months of age who enrolled in care increased from 13% in 2004--05 to 47% in 2012--13. Median CD4 count at enrollment in care increased from 563 in 2004--05 to 660 cells/μl in 2012--13 (p = \<0.0001). The proportion of children with CD4 count \<200 cells/μl and 200--349 cells/μl also declined from 2004--05 to 2012--13 but remained fairly stable among those whose CD4 count is \>350--499 cells/μl and \>500 cells/μl. Median CD4 count increased marginally in all age groups, with the highest increase among children 0--24 months (p = 0.04) and lowest among those aged 121--156 months (p = 0.26). The proportion of children classified as stage III or IV at enrollment decreased from 37% in 2004--05 to 20% in 2012--13. Median WAZ was -2 in 2004--05 and -1 in 2012--13 (p = \<0.0001).

10.1371/journal.pone.0169871.t002

###### Characteristics of children in the Central Africa IeDEA cohort by year of enrollment.

![](pone.0169871.t002){#pone.0169871.t002g}

                                            2004--05          2006--07          2008--09           2010--11           2012--13           *p*-value
  ----------------------------------------- ----------------- ----------------- ------------------ ------------------ ------------------ -----------
  [**Age (months) (n, %)**]{.ul}                                                                                                         
  Median (IQR)                              77.2(44.8,110)    74.5(35.6,111)    53.8(21.0,98.0)    40.5(12.3,90.7)    30.3(5.9,87.6)     \<0.0001
  0--24                                     80 (12.7)         114 (16.8)        195 (28.0)         272 (37.3)         321 (46.5)         \<0.0001
  25--60                                    151 (24.0)        157 (23.1)        178 (25.5)         165 (22.6)         124 (18.0)         
  61--84                                    126 (20.0)        118 (17.4)        98 (14.1)          83 (11.4)          64 (9.3)           
  85--120                                   155 (24.6)        155 (22.8)        119 (17.1)         108 (14.8)         89 (12.9)          
  121--156                                  118 (18.7)        136 (20.0)        107 (15.4)         101 (13.9)         92 (13.3)          
  [**Sex (n,%)**]{.ul}                                                                                                                   
  Male                                      291 (46.2)        337 (49.6)        360 (51.6)         344 (47.2)         337 (48.8)         0.3
  Female                                    339 (53.8)        343 (50.4)        337 (48.4)         385 (52.8)         353 (51.2)         
  [**Country (n,%)**]{.ul}                                                                                                               
  Burundi                                   NA                NA                194 (27.8)         277 (38.0)         251 (36.4)         \<0.0001
  DRC                                       268 (42.5)        256 (37.6)        289 (41.5)         291 (39.9)         203 (29.4)         
  Rwanda                                    362 (57.5)        424 (62.4)        214 (30.7)         161 (22.1)         236 (34.2)         
  [**CD4 count (n, %)**]{.ul}                                                                                                            
  Missing Data (Not in p-value)             93 (14.8)         91 (13.4)         282 (40.5)         330 (45.3)         452 (65.5)         \<0.0001
  Overall Median (IQR)                      563(275,901)      670(361,1056)     675(349,1104)      695(398,1084)      660(339,1071)      0.001
  \<200                                     96 (17.9)         75 (12.7)         56 (13.5)          53 (13.3)          29 (12.2)          
  200--349                                  81 (15.1)         63 (10.7)         48 (11.6)          31 (7.8)           31 (13.0)          
  \>350--499                                64 (11.9)         82 (13.9)         45 (10.8)          47 (11.8)          20 (8.4)           
  \>500                                     296 (55.1)        369 (62.6)        266 (64.1)         268 (67.2)         158 (66.4)         
  **Median CD4 count by age (IQR)**                                                                                                      
  0--24 month                               995 (542, 1629)   1240 (923, 2009   1176 (675, 1912)   1066 (667, 1695)   1012 (672, 1664)   0.04
  25--60 months                             778 (395, 1040)   760 (491, 1207)   842 (475, 1137)    779 (527, 1224)    851 (596, 1161)    0.55
  61--84 months                             555 (338, 832)    685 (351, 1003)   635 (276, 974)     633 (397, 920)     671 (439, 857)     0.61
  85--120 months                            424 (201, 669)    480 (277, 828)    500 (270, 823)     499 (247, 840)     441 (214, 686)     0.41
  121--156 months                           331 (181, 577)    397 (235, 692)    366 (169, 612)     370 (108, 704)     505 (298, 871)     0.26
  n for 0--24 months                        63                92                89                 102                46                 
  n for 25--60 months                       129               144               113                108                56                 
  n for 61--84 months                       112               105               68                 56                 33                 
  n for 85--120 months                      134               135               74                 65                 50                 
  n for 121--156 months                     99                113               71                 68                 53                 
  [**WHO clinical stage (n,%)**]{.ul}                                                                                                    
  Missing data (Not in p-value)             233 (37.0)        260 (38.2)        215 (30.8)         240 (32.9)         237 (34.4)         \<0.0001
  I                                         57 (9.0)          70 (10.3)         129 (18.5)         152 (20.9)         203 (29.4)         
  II                                        108 (17.1)        135 (19.9)        130 (18.6)         140 (19.2)         112 (16.2)         
  III                                       206 (32.7)        200 (29.4)        200 (28.7)         172 (23.6)         123 (17.8)         
  IV                                        26 (4.1)          15 (2.2)          23 (3.3)           25 (3.4)           15 (2.2)           
  [**Weight-for-age Z-score (n,%)**]{.ul}                                                                                                
  Missing data (Not in p-value)             220 (34.9)        255 (37.5)        178 (25.5)         235 (32.2)         222 (32.2)         
  Median (IQR)                              -2.2(-3.4,-1.1)   -1.9(-3.2,-0.8)   -1.6 (-2.9--0.6)   -1.7(-3.1,-0.5)    -1.4(-2.5,-0.2)    \<0.0001
  \>-2                                      181 (44.1)        220 (51.8)        299 (57.6)         277 (56.1)         299 (63.9)         \<0.0001
  -3 to -2                                  106 (25.9)        79 (18.6)         98 (18.9)          84 (17.0)          88 (18.8)          
  \<-3                                      123 (30.0)        126 (29.6)        122 (23.5)         133 (26.9)         81 (17.3)          

Characteristics of children at care enrollment by country are shown in Tables [3](#pone.0169871.t003){ref-type="table"}--[5](#pone.0169871.t005){ref-type="table"}. In Burundi, the median age decreased from 53.5 months in 2008--09 to 33.0 months in 2010--11, and then increased to 49.7 months in 2012--13. In the DRC, a similar trend was observed with the median age decreasing from 76.8 months in 2004--05 to 40.7 months in 2012--13. However, in Rwanda, though the median age in 2004--05 and 2006--07 was similar to that observed in DRC, it decreased continuously to 11.4 months in 2012--13. The proportion of children ≤24 months of age mostly drove the decreasing trend in median age at enrollment across countries. Between 2010--11 and 2012--13, this proportion more than doubled from 32.3% to 66.1% in Rwanda, changed slightly in DRC (from 35.0% to 37.7%), but decreased in Burundi, from 43% to 36%.

10.1371/journal.pone.0169871.t003

###### Characteristics at enrollment in care of children in Central Africa IeDEA in Burundi by year of enrollment.
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  --------------------------------------------------------------------------------------------------------------------------------------------
                                            2004--05\           2006--07\          2008--09\           2010--11\     2012--13\     *p*-Value
                                            (n, %)              (n,%)              n = 194 (%)         n = 277 (%)   n = 251 (%)   
  ----------------------------------------- ------------------- ------------------ ------------------- ------------- ------------- -----------
  [**Age (months)(n,%)**]{.ul}                                                                                                     

  Median (IQR)                              53.5 (18.5, 98.4)   33.0 (8.1, 93.5)   49.7 (11.6, 97.4)   0.19                        

  0--24                                     55 (28.3)           118 (42.6)         90 (35.9)           0.17                        

  25--60                                    51 (26.3)           53 (19.1)          50 (19.9)                                       

  61--84                                    23 (11.9)           27 (9.6)           27 (10.8)                                       

  85--120                                   35 (18.0)           40 (14.4)          42 (16.7)                                       

  121--156                                  30 (15.5)           39 (14.1)          42 (16.7)                                       

  [**Sex (n,%)**]{.ul}                                                                                                             

  Male                                      99 (51.0)           123 (44.4)         118 (47.0)          0.36                        

  Female                                    95 (49.0)           154 (55.6)         133 (53.0)                                      

  [**CD4 count (n,%)**]{.ul}                                                                                                       

  Missing Data (Not in P-value)             152 (78.4)          217 (78.34)        187 (74.5)                                      

  Median (Q1,Q3)                            712(512,1124)       562(347,988)       698(418,978)        0.25                        

  \<200                                     5 (11.9)            8 (13.3)           4 (6.3)             0.03                        

  200--349                                                      7 (11.7)           7 (10.9)                                        

  350--499                                  4 (9.5)             11 (18.3)          6 (9.4)                                         

  \>500                                     33 (78.6)           34 (56.7)          47 (73.4)                                       

  Median CD4 for 0--24 months               1092(750, 2010)     828(491,1427)      1143(518,1978)      0.61                        

  Median CD4 for 25--60 months              987(536,1299)       843(386,1375)      943(618,1818)       0.64                        

  Median CD4 for 61--84 months              640(525,754)        446(315,985)       597(504,809)        0.76                        

  Median CD4 for 85--120 months             911(599,1178)       513(379,619)       582(312,775)        0.14                        

  Median CD4 for 121--156 months            497(279,638)        342(151,577)       616(408,924)        0.06                        

  n for 0--24 months                        4                   15                 10                                              

  n for 25--60 months                       12                  17                 11                                              

  n for 61--84 months                       9                   6                  11                                              

  n for 85--120 months                      9                   8                  16                                              

  n for 121--156 months                     8                   14                 16                                              

  [**WHO clinical stage (n,%)**]{.ul}                                                                                              

  Missing Data (Not in P-value)             92 (47.4)           147 (53.1)         56 (22.3)                                       

  Stage I                                   19 (18.6)           21 (16.2)          58 (29.7)           0.047                       

  Stage II                                  24 (23.5)           41 (31.5)          47 (24.1)                                       

  Stage III                                 46 (45.1)           55 (42.3)          77 (39.5)                                       

  Stage IV                                  13 (12.7)           13 (10.0)          13 (6.7)                                        

  [**Weight-for-age Z-score (n,%)**]{.ul}                                                                                          

  Missing Data (Not in P-value)             97 (50.0)           160 (57.8)         57 (22.7)                                       

  Median (Q1, Q3)                           -1.4(-2.3,-0.2)     -1.6(-3.4,-0.2)    -1.3(-2.5,0.3)      0.077                       

  \>-2                                      67 (69.1)           68 (58.1)          123 (63.4)          0.035                       

  -3 to -2                                  10 (10.3)           15 (12.8)          38 (19.6)                                       

  \<-3                                      20 (20.6)           34 (29.1)          33 (17.0)                                       
  --------------------------------------------------------------------------------------------------------------------------------------------

10.1371/journal.pone.0169871.t004

###### Characteristics at enrollment in care of children in Central Africa IeDEA in DRC by year of enrollment.
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  -------------------------------------------------------------------------------------------------------------------------------------------------
                                           2004--05\          2006--07\         2008--09\           2010--11\         2012--13\         *p*-Value
                                           n = 268 (%)        n = 256 (%)       n = 289 (%)         n = 291 (%)       n = 203 (%)       
  ---------------------------------------- ------------------ ----------------- ------------------- ----------------- ----------------- -----------
  [**Age (months) (n,%)**]{.ul}                                                                                                         

  Median (IQR)                             76.8 (43.3, 114)   66.1(29.8,103)    49.8 (16.3, 85.1)   42.4(15.4,86.8)   40.7(8.2,96.6)    \<0.0001

  0--24                                    35 (13.1)          53 (20.7)         96 (33.3)           102 (35.1)        75 (36.9)         \<0.0001

  25--60                                   68 (25.4)          66 (25.8)         74 (25.0)           75 (25.8)         49 (24.1)         

  61--84                                   52 (19.4)          42 (16.4)         41 (14.2)           38 (13.1)         21 (10.3)         

  85--120                                  61 (22.8)          51 (19.9)         42 (14.5)           43 (14.8)         28 (13.8)         

  121--156                                 52 (19.4)          44 (17.2)         33 (11.0)           33 (11.3)         30 (14.8)         

  [**Sex (n,%)**]{.ul}                                                                                                                  

  Male                                     123 (45.9)         125 (48.8)        144 (49.8)          149 (51.2)        105 (51.7)        0.7

  Female                                   145 (54.1)         131 (51.2)        145 (50.2)          142 (48.8)        98 (48.3)         

  [**CD4 count (n,%)**]{.ul}                                                                                                            

  Missing Data (Not in P-value)            11 (4.1)           17 (6.6)          90 (31.1)           62 (21.3)         102 (50.3)        

  Median (Q1,Q3)                           543(253,852)       631(273,1076)     618(293,1011)       656(364,1066)     610(316,1017)     0.09

  \<200                                    53 (20.6)          46 (19.2)         36 (18.1)           40 (17.5)         15 (14.9)         0.32

  200--349                                 31 (12.1)          20 (8.4)          26 (13.1)           16 (7.0)          13 (12.9)         

  350--499                                 38 (14.8)          29 (12.1)         21 (10.6)           27 (11.8)         9 (8.9)           

  \>500                                    135 (52.5)         144 (60.3)        116 (58.3)          146 (63.8)        64 (63.4)         

  Median CD4 for 0--24 months              1191(706,1757)     1204(765,1846)    1029(616,1912)      1066(576,1670)    1133(672,1292)    0.8

  Median CD4 for 25--60 months             607(275,942)       668(451,1096)     719(359,988)        759(448,1057)     640(511,1017)     0.44

  Median CD4 for 61--84 months             495(331,802)       668(199,976)      389(116,900)        618(438,855)      680(386,1285)     0.22

  Median CD4 for 85--120 months            431(188,649)       442(249,907)      377(195,627)        387(130,642)      431(252,612)      0.68

  Median CD4 for 121--156 months           317(133,577)       257(49,585)       295(100,579)        151(25,442)       365(113,547)      0.17

  n for 0--24 months                       35                 48                56                  68                18                

  n for 25--60 months                      63                 64                58                  64                31                

  n for 61--84 months                      52                 41                31                  34                12                

  n for 85--120 months                     57                 48                26                  35                19                

  n for 121--156 months                    50                 38                28                  28                21                

  [**WHO clinical stage (n,%)**]{.ul}                                                                                                   

  Missing Data (Not in P-value)            3 (1.1)            14 (5.5)          22 (7.6)            10 (3.4)          12 (5.9)          

  Stage I                                  29 (10.9)          40 (16.5)         71 (26.6)           83 (29.5)         109 (57.1)        \<0.0001

  Stage II                                 65 (24.5)          71 (29.3)         68 (25.5)           84 (29.9)         42 (22.0)         

  Stage III                                151 (57.0)         119 (49.2)        122 (45.7)          106 (37.7)        39 (20.4)         

  Stage IV                                 20 (7.5)           12 (5.0)          6 (2.2)             8 (2.8)           1 (0.5)           

  [**Weight-for-age Z-score(n,%)**]{.ul}                                                                                                

  Missing Data (Not in P-value)            3 (1.1)            3 (1.2)           2 (0.7)             1 (0.3)           5 (2.5)           

  Median (Q1, Q3)                          -2.4(-3.6,-1.3)    -2.1(-3.3,-1.0)   -1.9(-3.2,-0.7)     -2.1(-3.3,-0.9)   -1.4(-2.7,-0.5)   \<0.0001

  \>-2                                     106 (40.0)         119 (47.0)        147 (51.2)          141 (48.6)        127 (64.1)        0.0003

  -3 to -2                                 69 (26.0)          51 (20.2)         60 (20.9)           58 (20.0)         32 (16.2)         

  \<-3                                     90 (34.0)          83 (32.8)         80 (27.9)           91 (31.4)         39 (19.7)         
  -------------------------------------------------------------------------------------------------------------------------------------------------

10.1371/journal.pone.0169871.t005

###### Characteristics at enrollment in care of children in Central Africa IeDEA in Rwanda by year of enrollment.

![](pone.0169871.t005){#pone.0169871.t005g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------
                                            [2004--05]{.ul}\   [2006--07]{.ul}\   [2008--09]{.ul}\   [2010--11]{.ul}\    [2012--13]{.ul}\   *p*-Value
                                            n = 362 (%)        n = 424 (%)        n = 214 (%)        n = 161 (%)         n = 236 (%)        
  ----------------------------------------- ------------------ ------------------ ------------------ ------------------- ------------------ -----------
  [**Age (months) (n,%)**]{.ul}                                                                                                             

  Median (IQR)                              77.6 (45.6, 109)   78.4 (41.0, 116)   68.5 (27.7, 109)   50.7 (15.2, 97.0)   11.4 (2.2, 49.7)   \<0.0001

  0--24                                     45 (12.4)          61 (14.4)          44 (20.6)          52 (32.3)           156 (66.1)         \<0.0001

  25--60                                    83 (22.9)          91 (21.5)          53 (24.8)          37 (23.0)           25 (10.6)          

  61--84                                    74 (20.4)          76 (17.9)          34 (15.9)          18 (11.2)           16 (6.8)           

  85--120                                   94 (26.0)          104 (24.5)         42 (19.6)          25 (15.5)           19 (8.0)           

  121--156                                  66 (18.2)          92 (21.1)          41 (19.2)          29 (18.0)           20 (8.5)           

  [**Sex (n,%)**]{.ul}                                                                                                                      

  Male                                      168 (46.4)         212 (50.0)         117 (54.7)         72 (44.7)           114 (48.3)         0.28

  Female                                    194 (53.6)         212 (50.0)         97 (45.3)          89 (55.3)           122 (51.7)         

  [**CD4 count (n,%)**]{.ul}                                                                                                                

  Missing Data (Not in P-value)             82 (22.7)          74 (17.5)          40 (18.7)          51 (31.7)           163 (69.1)         \<0.0001

  Median (Q1,Q3)                            582(298,927)       681(377,1026)      736(376,1159)      801(598,1213)       741(301,1123)      0.0005

  \<200                                     43 (15.4)          29 (8.3)           15 (8.6)           5 (4.5)             10 (13.7)          

  200--349                                  50 (17.9)          43 (12.3)          22 (12.6)          8 (7.3)             11 (15.1)          

  350--499                                  26 (9.3)           53 (5.1)           20 (11.5)          9 (8.2)             5 (6.8)            

  \>500                                     161 (57.5)         225 (64.3)         117 (67.2)         88 (80.0)           47 (64.4)          

  Median CD4 for 0--24 months               800(259,1411)      1344(1014,2143)    1305(1106,1912)    1240(965,1971)      951(698,1559)      0.0075

  Median CD4 for 25--60 months              882(548,1199)      855(555,1254)      999(620,1213)      1000(665,1335)      983(696,1216)      0.5746

  Median CD4 for 61--84 months              648(390,934)       695(399,1016)      760(476,1266)      738(400,1017)       709(387,981)       0.6195

  Median CD4 for 85--120 months             378(212,727)       498(307,744)       461(302,819)       856(499,1117)       305(135,938)       0.0066

  Median CD4 for 121--156 months            345(224,568)       460(273,755)       385(254,612)       675(362,796)        586(301,1132)      0.0415

  n for 0--24 months                        28                 44                 29                 19                  18                 

  n for 25--60 months                       66                 80                 43                 27                  14                 

  n for 61--84 months                       60                 64                 28                 16                  10                 

  n for 85--120 months                      77                 87                 39                 22                  15                 

  n for 121--156 months                     49                 75                 35                 26                  16                 

  [**WHO clinical stage (n,%)**]{.ul}                                                                                                       

  Missing Data (Not in P-value)             230 (63.5)         246 (58.0)         101 (47.2)         83 51.6)            169 (71.6)         

  Stage I                                   28 (21.2)          30 (16.9)          39 (34.5)          48 (61.5)           36 (53.7)          0.0001

  Stage II                                  43 (32.6)          64 (36.0)          38 (33.6)          15 (19.2)           23 (34.3)          

  Stage III                                 55 (41.7)          81 (45.5)          32 (28.3)          11 (14.1)           7 (10.4)           

  Stage IV                                  6 (4.5)            3 (1.7)            4 (3.5)            4 (5.1)             1 (1.5)            

  [**Weight-for-age Z-score (n,%)**]{.ul}                                                                                                   

  Missing Data (Not in P-value)             217 (59.9)         252 (59.4)         79 (36.9)          74 (46.0)           160 (67.8)         

  Median (IQR)                              -1.8(-2.9,-0.9)    -1.7(-3.0,-0.6)    -1.4(-2.4,-0.6)    -0.9(-1.7,-0.1)     -1.6(-2.3,-0.4)    0.001

  \>-2                                      75 (51.7)          101 (58.7)         85 (63.0)          68 (78.2)           49 (64.5)          0.002

  -3 to -2                                  37 (25.5)          28 (16.3)          28 (20.7)          11 (12.6)           18 (23.7)          

  \<-3                                      33 (22.8)          43 (25.0)          22 (16.3)          8 (9.2)             9 (11.8)           
  -----------------------------------------------------------------------------------------------------------------------------------------------------

The proportion of children with WHO staging data who were classified as stage III or IV at enrollment in care in Burundi was 30%, 25% and 36% in 2008--09, 2010--11, and 2012--13, respectively. In the DRC, the proportion of children classified as stage III or IV was 64% in 2004--05 and decreased continuously to 20% in 2012--13, whereas the proportion in Rwanda decreased from a peak of 19% in 2006--2007 to 16% in 2008--09, 9.3% in 2010--11, and 3.4% in 2012--13. Nearly equal proportions of boys and girls enrolled in care in each country from 2004--13. Median WAZ increased progressively from 2004--13 in the DRC and Rwanda, but fluctuated in Burundi from 2008--09 to 2012--13.

[Table 6](#pone.0169871.t006){ref-type="table"} shows children's characteristics at ART initiation by year, from 2004 to 2013. The median age at ART initiation was 83.0 months in 2004--05, progressively decreased until 2010--11 to a median of 49.2 months, and then rose to 67.2 months in 2012--13 (p = \<0.0001). The proportion of ART initiators ≤24 months of age increased from 9.6% in 2004--05 to a peak of 29.2% in 2010--11, before declining to 24.2% in 2012--13. During the same period, the median CD4 count increased from 310 cells/μl in 2004--05 to 589 cells/μl in 2012--13 (p = \<0.0001). The proportion of children with median CD4 count \<200 at ART initiation decreased from 32% in 2004--05 to 13% in 2012--13 whereas it fluctuated or remained fairly stable among children with \>200 cells/μl. Median CD4 count at ART initiation increased among all age groups from 2004--05 to 2012--13, with the most significant increase observed among children aged 25--60 months (p = 0.0003).

10.1371/journal.pone.0169871.t006

###### Characteristics of children in the Central Africa IeDEA cohort by year of ART initiation.

![](pone.0169871.t006){#pone.0169871.t006g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
                                             [2004--05]{.ul}\    [2006--07]{.ul}\   [2008--09]{.ul}\     [2010--11]{.ul}\   [2012--13]{.ul}\    *p*-value
                                             n = 280 (%)         n = 431 (%)        n = 413 (%)          n = 468 (%)        n = 466 (%)         
  ------------------------------------------ ------------------- ------------------ -------------------- ------------------ ------------------- -----------
  [**Age (months) (n, %)**]{.ul}                                                                                                                

  Median (IQR)                               83.0 (49.8, 117)    79.3 (38.5, 117)   71.3 (27.8, 112)     49.9(21.7,106)     67.2(25.2,115)      \<0.0001

  0--24                                      27 (9.6)            65 (15.1)          87 (21.1)            133 (28.42)        110 (23.6)          \<0.0001

  25--60                                     66 (23.6)           102 (23.7)         94 (22.8)            127 (27.14)        108 (23.2)          

  61--84                                     52 (18.6)           63 (14.3)          55 (13.3)            45 (9.62)          52 (11.2)           

  85--120                                    73 (26.1)           103 (23.9)         94 (22.8)            79 (16.8)          90 (19.3)           

  121--156                                   62 (22.1)           98 (22.7)          83 (20.1)            84 (17.95)         106 (22.7)          

  [**Sex (n,%)**]{.ul}                                                                                                                          

  Male                                       136 (48.6)          227 (52.7)         220 (53.3)           239 (51.07%)       230 (49.4)          0.73

  Female                                     144 (51.4)          204 (47.3)         193 (46.3)           229 (48.93%)       236 (50.6)          

  [**Country (n,%)**]{.ul}                                                                                                                      

  Burundi                                    N/A                 N/A                28 (6.8)             63 (13.5)          208 (44.6)          \<0.0001

  DRC                                        165 (58.9)          227 (52.7)         214 (51.8)           265 (56.6)         131 (28.1)          

  Rwanda                                     115 (41.1)          204 (47.3)         171 (41.4)           140 (29.9)         127 (27.2)          

  [**CD4 count (n, %)**]{.ul}                                                                                                                   

  Missing Data (Not in p-value)              23 (8.2)            29 (6.7)           71 (17.2)            90 (19.2)          185 (39.7)          

  Median (IQR)                               310 (167, 600)      471 (228, 950)     437 (246, 879)       560 (317,1066)     589 (315,1113)      

  \<200                                      83 (32.3)           85 (21.1)          62 (18.1)            58 (15.3)          37 (13.17)          \<0.0001

  200--349                                   62 (24.1)           73 (18.2)          84 (24.6)            57 (15.1)          58 (20.6)           \<0.0001

  350--499                                   35 (13.6)           54 (13.4)          39 (11.4)            57 (15.1)          32 (11.4)           

  \>500                                      77 (30.0)           190 (47.3)         157 (45.9)           206 (54.5)         154 (54.1)          

  [**Median by age group (IQR)**]{.ul}                                                                                                          

  0--24 months                               883 (611, 1291)     1140 (832, 1784)   1073 (684, 1784)     1158 (705, 1796)   1267 (845, 2141)    0.06

  25--60 months                              469 (240, 838)      628 (425, 1029)    726 (360, 1042)      703 (435, 1151)    \_889 (610, 1358)   0.0003

  61--84 months                              332 (178, 482)      544 (264, 867)     432 (227, 697)       546 (329, 684)     597 (329, 655)      0.01

  85--120 months                             219 (120, 378)      339 (204, 615)     302 (214, 419)       327 (174, 462)     338 (217, 655)      0.003

  121--156 months                            223 (109, 321)      249 (131, 424)     267 (169, 358)       315 (97, 428)      342 (246, 470)      0.01

  n for 0--24 months                         27                  62                 66                   102                60                  

  n for 25--60 months                        58                  94                 79                   102                57                  

  n for 61--84 months                        49                  61                 47                   38                 33                  

  n for 85--120 months                       67                  95                 81                   64                 63                  

  n for 121--156 months                      56                  90                 69                   72                 68                  

  [**WHO clinical stage (n,%)**]{.ul}                                                                                                           

  Missing data (Not in p-value)              68 (24.3)           71 (16.5)          70 (16.9)            64 (13.68%)        62 (13.3)           

  I                                          17 (6.1)            45 (10.4)          58 (14.0)            81 (17.31%)        109 (23.4)          \<0.0001

  II                                         40 (14.3)           91 (21.1)          88 (21.3)            93 (19.87%)        99 (21.2)           

  III                                        136 (48.6)          206 (47.8)         183 (44.3)           199 (42.52%)       179 (38.4)          

  IV                                         19 (6.8)            18 (4.2)           14 (3.4)             31 (6.62%)         17 (3.6)            

  [**Weight-for-age Z-score (n, %)**]{.ul}                                                                                                      

  Missing data (Not in p-value)              71                  88                 60                   62                 33                  

  Median (IQR)                               -2.6 (-3.8, -1.6)   -2.0 (-3.2, 0.9)   -2.0 (-.3.0, -0.9)   -1.8(-3.0,-0.7)    -1.5(-2.6,-0.4)     \<0.0001

  \>-2                                       70 (33.5)           176 (51.3)         181 (51.3)           221 (54.4)         274 (63.3)          \<0.0001

  -3 to -2                                   53 (25.4)           70 (20.4)          83 (23.5)            85 (20.9)          86 (19.9)           

  \<-3                                       86 (41.1)           97 (28.3)          89 (25.2)            100 (24.6)         73 (16.9)           
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

The overall proportion of children without WHO clinical staging data declined from 24% in 2004--05 to about 13% in 2012--13. Among children with WHO staging data reported, the proportion of those classified as stage III or IV decreased from 54% 2004--05 to 42% to 2012--13 (p = \<0.0001). There was improvement in the median WAZ, from -2 in 2004--05 to -1 in 2012--13 (p = \<0.0001).

Tables [7](#pone.0169871.t007){ref-type="table"}--[9](#pone.0169871.t009){ref-type="table"} depict children's characteristics at ART initiation in each country. In Burundi, the median age was 71.4 months in 2008--09 but remained fairly stable from 2010--13. The proportion of children ≤24 months of age who initiated ART from 2008--09 to 2012--13 increased from 11% to 16%. In the DRC, the median age remained stable at \~75 months between 2004--07 then declined to 40.2 months in 2010--11 before rising to 59.9 months in 2012--13. The proportion of ART initiators ≤24 months of age increased from 11.5% in 2004--05 to 33% in 2010--11, before dropping to 24% in 2012--13. In Rwanda, the median age at ART initiation declined from 90.2 months in 2004--05 to 44.8 months in 2012--13, driven by the increasing proportion of children ≤24 months of age, which rose from 7% to 35% over the same period. The median CD4 count increased by about 200 and 300 cells/μl in the DRC and Rwanda respectively between 2004--05 and 2012--13, and by more than 100 cells/μl in Burundi from 2008--09 to 2012--13. The proportion of children classified as WHO clinical stage III or IV in each country was noteworthy. Nearly half and slightly more than half of children in Burundi and the DRC, respectively, and nearly one-third of children in Rwanda were classified as stage III or IV. Considerable proportions of children in the three countries were underweight at ART initiation, although these proportions continuously declined from 2004-05-2012-13.

10.1371/journal.pone.0169871.t007

###### Characteristics at ART initiation of children in Central Africa IeDEA in Burundi by year of ART initiation.

![](pone.0169871.t007){#pone.0169871.t007g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------
                                           [2004--05]{.ul}\   [2006--07]{.ul}\   [2008--09]{.ul}\   [2010--11]{.ul}\   [2012--13]{.ul}\   [*p*-Value]{.ul}
                                           (n, %)             (n, %)             n = 28 (%)         n = 63 (%)         n = 208 (%)        
  ---------------------------------------- ------------------ ------------------ ------------------ ------------------ ------------------ ------------------
  [**Age (months) (n,%)**]{.ul}                                                                                                           

  Median (IQR)                             71.4 (41.0, 124)   80.4 (32.6, 123)   79.1 (35.9, 123)   0.97                                  

  0--24                                    3 (10.7)           10 (15.9)          34 (16.3)          0.89                                  

  25--60                                   8 (28.6)           18 (28.6)          48 (23.1)                                                

  61--84                                   5 (17.9)           7 (11.1)           27 (13.0)                                                

  85--120                                  3 (10.7)           11 (17.5)          43 (20.7)                                                

  121--156                                 9 (32.1)           17 (27.0)          56 (26.9)                                                

  [**Sex (n,%)**]{.ul}                                                                                                                    

  Male                                     16 (57.1)          34 (54.0)          102 (49.0)         0.62                                  

  Female                                   12 (42.9)          29 (46.0)          106 (51.0)                                               

  [**CD4 count (n,%)**]{.ul}                                                                                                              

  Missing Data (Not in P-value)            20 (71.4)          31 (49.2)          130 (62.5)                                               

  Median (Q1,Q3)                           519(168,662)       383(215,599)       644(376,1080)      0.002                                 

  \<200                                    3 (37.5)           7 (21.9)           7 (9.0)            0.013                                 

  200--349                                                    5 (15.6)           9 (11.5)                                                 

  350--499                                                    11 (34.4)          16 (20.5)                                                

  \>500                                    5 (62.5)           9 (28.1)           46 (59.0)                                                

  Median CD4 for 0--24 months                                 623(447,828)       565(293,1934)      0.8383                                

  Median CD4 for 25--60 months             632(163,1100)      419(358,637)       736(618,1190)      0.1797                                

  Median CD4 for 61--84 months             603(511,695)       333(264,392)       840(418,1225)      0.0882                                

  Median CD4 for 85--120 months            526(526,526)       389(155,493)       644(411,1190)      0.033                                 

  Median CD4 for 121--156 months           173(151,629)       325(132,575)       416(343,780)       0.2182                                

  n for 0--24 months                                          3                  8                                                        

  n for 25--60 months                      2                  8                  13                                                       

  n for 61--84 months                      2                  4                  13                                                       

  n for 85--120 months                     1                  7                  22                                                       

  n for 121--156 months                    3                  10                 22                                                       

  [**WHO clinical stage (n,%)**]{.ul}                                                                                                     

  Missing Data (Not in P-value)            16 (57.1)          21 (33.3)          17 (8.2)                                                 

  Stage I                                                     1 (2.38)           27 (14.1)          0.049                                 

  Stage II                                                    8 (19.05)          33 (17.3)                                                

  Stage III                                10 (83.3)          32 (76.19)         116 (60.7)                                               

  Stage IV                                 2 (16.7)           1 (2.38)           15 (7.9)                                                 

  [**Weight-for-age Z-score(n,%)**]{.ul}                                                                                                  

  Missing Data (Not in P-value)            18 (64.3)          30 (47.6)          16 (7.7)                                                 

  Median (Q1, Q3)                          -1.0(-1.6,-0.6)    -2.3(-3.2,-1.3)    -1.5(-2.7,-0.4)    0.07                                  

  \>-2                                     9 (90.0)           16 (48.5)          120 (62.5)         0.16                                  

  -3 to -2                                 1 (10.0)           7 (21.2)           35 (18.2)                                                

  \<-3                                                        10 (30.3)          37 (19.3)                                                
  ----------------------------------------------------------------------------------------------------------------------------------------------------------

10.1371/journal.pone.0169871.t008

###### Characteristics at ART initiation of children in Central Africa IeDEA in the DRC by year of ART initiation.

![](pone.0169871.t008){#pone.0169871.t008g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
                                           [2004--05]{.ul}\   [2006--07]{.ul}\   [2008--09]{.ul}\    [2010--11]{.ul}\   [2012--13]{.ul}\   [*p*-Value]{.ul}
                                           n = 165 (%)        n = 227 (%)        n = 214 (%)         n = 265 (%)        n = 131 (%)        
  ---------------------------------------- ------------------ ------------------ ------------------- ------------------ ------------------ ------------------
  [**Age (months) (n,%)**]{.ul}                                                                                                            

  Median (IQR)                             74.8 (45.6, 109)   74.9 (35.9, 113)   54.3 (21.9, 96.4)   40.2(18.5,84.4)    59.9(25.2,111)     \<0.0001

  0--24                                    19 (11.5)          36 (15.9)          61 (28.5)           87 (32.8)          31 (23.7)          \<0.0001

  25--60                                   44 (26.7)          57 (25.2)          54 (25.2)           83 (31.3)          35 (26.7)          

  61--84                                   31 (18.8)          37 (16.3)          30 (14.0)           26 (9.8)           14 (10.7)          

  85--120                                  38 (23.0)          47 (20.7)          43 (20.1)           34 (12.8)          25 (19.1)          

  121--156                                 33 (20.0)          50 (22.0)          26 (12.1)           35 (13.2)          26 (19.8)          

  [**Sex (n,%)**]{.ul}                                                                                                                     

  Male                                     80 (48.5)          108 (47.6)         110 (51.4)          136 (51.3)         67 (51.1)          0.9

  Female                                   85 (51.5)          119 (52.4)         104 (48.6)          129 (48.7)         64 (48.9)          

  [**CD4 count (n,%)**]{.ul}                                                                                                               

  Missing Data (Not in P-value)            8 (4.9)            8 (3.5)            36 (16.8)           42 (15.9)          29 (22.1)          

  Median (Q1,Q3)                           359(162,675)       552(218,1015)      545(233,911)        656(317,1109)      547(278,963)       \<0.0001

  \<200                                    48 (30.6)          50 (22.8)          39 (21.9)           40 (17.9)          18 (17.7)          0.0002

  200--349                                 29 (18.5)          26 (11.9)          26 (14.6)           24 (10.8)          21 (20.6)          

  350--499                                 22 (14.0)          30 (13.7)          21 (11.8)           26 (11.7)          9 (8.8)            

  \>500                                    58 (36.9)          113 (51.6)         92 (51.7)           133 (59.6)         54 (52.9)          

  Median CD4 for 0--24 months              838(667,1282)      1108(757,1827)     888(655,1430)       1117(667,1774)     1237(845,2047)     0.1543

  Median CD4 for 25--60 months             443(215,892)       630(389,1061)      708(347,984)        758(428,1067)      640(511,1029)      0.152

  Median CD4 for 61--84 months             335(189,574)       667(125,931)       378(211,697)        591(349,737)       439(319,601)       0.2452

  Median CD4 for 85--120 months            224(68.0,491)      456(233,866)       266(158,533)        267(102,474)       262(87.0,337)      0.0902

  Median CD4 for 121--156 months           237(116,377)       236(60.0,438)      169(41.0,484)       115(28.0,360)      310(133,370)       0.4592

  n for 0--24 months                       19                 35                 45                  71                 24                 

  n for 25--60 months                      39                 57                 48                  71                 25                 

  n for 61--84 months                      30                 37                 26                  22                 9                  

  n for 85--120 months                     36                 44                 36                  28                 20                 

  n for 121--156 months                    33                 46                 23                  31                 24                 

  [**WHO clinical stage (n,%)**]{.ul}                                                                                                      

  Missing Data (Not in P-value)                                                                                         1 (0.8)            \<0.0001

  Stage I                                  9 (5.5)            28 (12.3)          25 (11.7)           49 (18.5)          41 (31.5)          

  Stage II                                 27 (16.4)          60 (26.4)          62 (29.0)           62 (23.4)          41 (31.5)          

  Stage III                                115 (69.7)         126 (55.5)         123 (57.5)          134 (50.6)         47 (36.2)          

  Stage IV                                 14 (8.5)           13 (5.7)           4 (1.9)             20 (7.6)           1 (0.8)            

  [**Weight-for-age Z-score(n,%)**]{.ul}                                                                                                   

  Missing Data (Not in P-value)                               1 (0.44)           1 (0.47)                                                  

  Median (Q1, Q3)                          -2.6(-3.9,-1.6)    -2.0(-3.2,-0.9)    -2.1(-3.2,-1.1)     -2.0(-3.2,-0.8)    -1.7(-2.7,-0.6)    \<0.0001

  \>-2                                     58 (35.15)         116 (51.33)        101 (47.42)         132 (49.81)        78 (59.54)         0.0006

  -3 to -2                                 36 (21.82)         44 (19.47)         50 (23.47)          57 (21.51)         30 (22.90)         

  \<-3                                     71 (43.03)         66 (29.20)         62 (29.11)          76 (28.68)         23 (17.56)         
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

10.1371/journal.pone.0169871.t009

###### Characteristics at ART initiation of children in Central Africa IeDEA in Rwanda by year of ART.

![](pone.0169871.t009){#pone.0169871.t009g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------
                                           [2004--05]{.ul}\   [2006--07]{.ul}\   [2008--09]{.ul}\   [2010--11]{.ul}\   [2012--13]{.ul}\   [*p*-Value]{.ul}
                                           n = 115 (%)        n = 204 (%)        n = 171 (%)        n = 140 (%)        n = 127 (%)        
  ---------------------------------------- ------------------ ------------------ ------------------ ------------------ ------------------ ------------------
  [**Age (months) (n,%)**]{.ul}                                                                                                           

  Median (IQR)                             90.2 (56.1, 120)   89.2 (42.0, 119)   90.7 (47.1, 123)   71.3 (23.4, 116)   44.8 (12.7, 105)   \<0.0001

  0--24                                    8 (7.0)            29 (14.2)          23 (13.4)          36 (25.7)          45 (35.4)          \<0.0001

  25--60                                   22 (19.1)          45 (22.1)          32 (18.7)          26 (18.6)          25 (19.7)          

  61--84                                   21 (18.3)          26 (12.7)          20 (11.7)          12 (8.6)           11 (8.7)           

  85--120                                  35 (30.4)          56 (27.4)          48 (28.1)          34 (24.3)          22 (17.3)          

  121--156                                 29 (25.2)          48 (23.5)          48 (28.1)          32 (22.9)          24 (18.9)          

  [**Sex (n,%)**]{.ul}                                                                                                                    

  Male                                     56 (48.7)          114 (55.9)         94 (55.0)          69 (49.3)          61 (48.0)          0.47

  Female                                   59 (51.3)          90 (44.1)          77 (45.0)          71 (50.7)          66 (52.0)          

  [**CD4 count (n,%)**]{.ul}                                                                                                              

  Missing Data (Not in P-value)            15 (13.0)          21 (10.3)          15 (8.8)           17 (12.1)          26 (20.5)          

  Median (Q1,Q3)                           263(167,441)       385(234,821)       350(264,779)       526(324,1033)      579(305,1310)      \<0.0001

  \<200                                    35 (35.00)         35 (19.13)         20 (12.82)         11 (8.94)          12 (11.88)         \<0.0001

  200--349                                 33 (33.00)         47 (25.68)         58 (37.18)         28 (22.76)         28 (27.72)         

  350--499                                 13 (13.00)         24 (13.11)         18 (11.54)         20 (16.26)         7 (6.93)           

  \>500                                    19 (19.00)         77 (42.08)         60 (38.46)         64 (52.03)         54 (53.47)         

  Median CD4 for 0--24 months              1087(233,1332)     1146(993,1784)     1207(1106,1854)    1479(894,1983)     1504(1010,2219)    0.3412

  Median CD4 for 25--60 months             469(262,698)       625(452,874)       749(458,1064)      1113(634,1532)     1275(782,2178)     0.0001

  Median CD4 for 61--84 months             325(167,441)       500(280,751)       447(282,698)       548(381,694)       481(251,801)       0.236

  Median CD4 for 85--120 months            212(124,314)       295(167,407)       304(238,362)       355(295,433)       332(205,369)       0.0034

  Median CD4 for 121--156 months           216(98.0,293)      252(183,381)       283(236,352)       336(254,536)       334(282,391)       0.0041

  n for 0--24 months                       8                  27                 21                 28                 28                 

  n for 25--60 months                      19                 37                 29                 23                 19                 

  n for 61--84 months                      19                 24                 19                 12                 11                 

  n for 85--120 months                     31                 51                 44                 29                 21                 

  n for 121--156 months                    23                 44                 43                 31                 22                 

  [**WHO clinical stage (n,%)**]{.ul}                                                                                                     

  Missing Data (Not in P-value)            68 (59.1)          71 (34.8)          54 (31.6)          43 (30.7)          44 (34.7)          \<0.0001

  Stage I                                  8 (17.0)           17 (12.8)          33 (28.2)          31 (32.0)          41 (49.4)          

  Stage II                                 13 (27.7)          31 (23.3)          26 (22.2)          23 (23.7)          25 (30.1)          

  Stage III                                21 (44.7)          80 (60.2)          50 (42.7)          33 (34.0)          16 (19.3)          

  Stage IV                                 5 (10.6)           5 (3.8)            8 (6.8)            10 (10.3)          1 (1.2)            

  [**Weight-for-age Z-score(n,%)**]{.ul}                                                                                                  

  Missing Data (Not in P-value)            71 (61.7)          87 (42.7)          41 (24.0)          32 (22.9)          17 (13.4)          \<0.0001

  Median (Q1, Q3)                          -2.6(-3.3,-1.7)    -2.0(-3.1,-0.9)    -1.8(-2.6,-0.7)    -1.3(-2.4,-0.5)    -1.3(-2.3,-0.2)    \<0.0001

  \>-2                                     12 (27.3)          60 (51.3)          71 (54.6)          73 (67.6)          76 (69.1)          

  -3 to -2                                 17 (38.6)          26 (22.2)          32 (24.6)          21 (19.4)          21 (19.1)          

  \<-3                                     15 (34.1)          31 (26.5)          27 (20.8)          14 (13.0)          13 (11.8)          
  ----------------------------------------------------------------------------------------------------------------------------------------------------------

[Fig 1](#pone.0169871.g001){ref-type="fig"} depicts the trend in the proportion of children initiated on ART within three months of their enrollment in care. Before 2006, 34% of children were initiated on ART within three months of their enrollment into care. The proportion increased slightly to 40% in 2006--07 but remained fairly stable from 2008--13 at about one-third of children who enrolled in care. In [Fig 2](#pone.0169871.g002){ref-type="fig"}, we show the median age at enrollment into care in all countries from 2004-05-2012-13. Overall, age at enrollment into care continually declined in all countries until 2010--11. After 2011, age at enrollment increased in Burundi, plateaued in the DRC and continued to decline in Rwanda. As shown in [Fig 3](#pone.0169871.g003){ref-type="fig"}, overall median age at ART initiation declined until 2010--2011 and then rose slightly in 2012--2013. In [Fig 4](#pone.0169871.g004){ref-type="fig"}, we show the median time from enrollment in care to ART initiation among initiators by age group.

![Proportion of children initiating ART within 3 months.](pone.0169871.g001){#pone.0169871.g001}

![Median age at enrollment in HIV care.](pone.0169871.g002){#pone.0169871.g002}

![Median age at ART initiation.](pone.0169871.g003){#pone.0169871.g003}

![Median time from enrollment in care to ART initiation by age group.](pone.0169871.g004){#pone.0169871.g004}

Discussion {#sec010}
==========

Early HIV diagnosis, enrollment in care, and ART initiation are critical to halt the rapid progression of HIV disease and reduce mortality in HIV-infected children \[[@pone.0169871.ref021]\]. Our study describes trends in characteristics of children enrolling in HIV care and initiating ART between 2004 and 2013 in the three Central African countries of Burundi, the DRC, and Rwanda to assess whether changes in the characteristics of children reflect changes in WHO guidelines for progressively earlier ART initiation.

Our results show that in all three countries the median age at enrollment in care (a proxy for HIV diagnosis) substantially decreased from 2004 to 2013, driven mainly by the increasing proportion of children ≤24 months of age, with a substantial increase observed in Rwanda and smaller increases in the DRC and Burundi. In Rwanda, for example, this increase reflects expanded access to DNA PCR for early infant diagnosis (EID) and the resulting increase in population coverage of EID from 28% to 72% from 2008--2011 after the country integrated EID with vaccination programs and invested in a robust mobile phone reporting system \[[@pone.0169871.ref022]\]. It is equally likely that increases in Rwanda reflect the effectiveness of the country's ART program, considered one of the most effective for adults in the world also applies to children due to the availability of resources through PEPFAR, the Global Fund and others.

Along with the increasing proportion of children who were ≤24 months of age at enrollment, the median CD4 count at entry into care also increased over time from 563 in 2004--05 to 660 cells/μl in 2012--13, with similar increases in median CD4 count at ART initiation (310 in 2004--05 to 589 cells/μl in 2012--13). Further, the median CD4 count for all age groups increased at both enrolment into care and at ART initiation from 2004-05-2012-13 as shown in Tables [2](#pone.0169871.t002){ref-type="table"} and [3](#pone.0169871.t003){ref-type="table"}. These results suggest that children 0--24 months and those 25--60 months were enrolling in care or initiating ART with higher CD4 cell counts compared with older children who enrolled in care or initiated ART with lower CD4 cell counts.

The likelihood of rapid progression of HIV disease and death among perinatally-infected children, and the evidence that early initiation of ART substantially reduces morbidity and mortality \[[@pone.0169871.ref008]\] led to the WHO's 2010 recommendation for ART in all children \<12 months regardless of CD4 count or clinical stage \[[@pone.0169871.ref009]\]. Our results show a significant decrease (p = \<0.0001) in the median age at both enrollment in care and at ART initiation. Although some progress can be inferred on the basis of the results presented here, for example the falling median age at enrollment and ART initiation, there remains a substantial gap between the proportions of children \<24 months who enrolled in care and those who initiated ART. Nonetheless, based on our analysis, we believe that the increase in CD4 count is due to children enrolling at younger ages versus being less sick at enrollment in care.

With regard to the number of children initiating ART, we observed that the number of children initiating ART in our sample is lower than those reported by Tene, et. al. \[[@pone.0169871.ref028]\] among children in Rwanda. The lower number of children initiating ART in our sample may be due to the selection of the clinics in our sample, which may not adequately represent the general population of pediatric HIV cohort, especially in Rwanda or may in fact reflect the proportion of children who are likely deceased or were lost to follow up and therefore unable to initiate ART. While this lack of representative sample is a limitation of our study, the findings presented are nonetheless critically important to highlight how changing guidelines are impacting on enrollment in care and initiation of ART among pediatric cohort in the sites where we obtained data.

While in-depth analyses are needed to fully understand the reasons for this gap, it is likely due to numerous structural factors, including time between sample collection and return of DNA PCR results, which is done centrally in all countries. Similarly, recent evidence from Zimbabwe showed that the lack of training in pediatric HIV among primary care providers is a strong barrier to successful implementation of comprehensive quality HIV service for children in extremely resource-poor settings like Central Africa \[[@pone.0169871.ref023]\]

The proportion of children without WHO staging data at both enrollment in care and ART initiation declined over time, it is plausible but hard to know how this could have biased our findings and/or in what direction although our focus in reporting the lack of WHO staging data was to highlight the importance of WHO staging in determining at what stage of disease classification children were enrolling in care or initiating ART. We note this as a limitation of the study.

Malnutrition, weight loss and failure to thrive are important clinical features in children presenting with AIDS and have been identified as causes of morbidity and mortality \[[@pone.0169871.ref024], [@pone.0169871.ref025]\]. Consistent with these studies \[[@pone.0169871.ref024]--[@pone.0169871.ref027]\], our median WAZ results suggest that many children in the cohort are either moderately or severely underweight, an indication of advanced disease, especially in the DRC where over half of children who enrolled in care through 2010--11 have a WAZ \<-2. Again, this suggests that children who are considerably underweight when they enrolled in care or initiated ART may be presenting with advanced stages of the disease.

To our knowledge, this is the first study in Central Africa that combines data from 3 countries to examine trends in demographic and clinical characteristics of children at HIV care enrollment and at ART initiation. A strength of our analysis is that it included Rwanda, a country with robust data at the forefront of scaling HIV services and high retention rates among pediatric HIV patients \[[@pone.0169871.ref028]\], as well as Burundi and the DRC, two countries that consistently lag behind in pediatric HIV treatment and from which there are limited data. It is worth noting the different sample sizes, characteristics and non-representativeness of selected clinics in our sample. The participating clinics in CA-IeDEA countries are not a representative sample of clinics from those countries, and may include those with more technical capacity. In addition, our analyses are purely descriptive and in the absence of any strong evidence, it is difficult to attribute causation or to any other outcomes such as loss to follow up, death and transfers or to state categorically that the changes we observed are in response to policy changes. We have only recently begun to collect data on these outcomes, thus a limitation of our analysis is the inability to explore causal relationships behind the observed trends or directly test the effect of changing guidelines. Nevertheless, it seems highly plausible that the changes we observed may be a response to changes in guidelines even though other factors, such as increased donor funding and health system response to pediatric HIV care may have contributed to the observed changes. It is worth stating that in-depth analyses are needed to identify barriers to timely HIV diagnosis, enrollment into care, and ART initiation among children in the region. This is critical because Central and West Africa have the highest under five mortality worldwide \[[@pone.0169871.ref029]\], and further analyses are needed to examine the trends in outcomes (lost-to-follow-up, mortality) among HIV-infected children enrolled in care in this region.

Conclusion {#sec011}
==========

The proportion of children 24 months of age or younger at enrollment into HIV care in CA-IeDEA participating clinics has increased since 2004. However, this increase has not fully translated into early initiation of ART. Further analyses are needed to identify barriers to timely initiation of ART among children in HIV care.

The authors acknowledge the efforts of the entire Central Africa IeDEA community and clinic staff at various HIV sites tasked with collecting the data used for this analysis.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: **Conceptualization:** AAA AE DH QS KA MY.**Data curation:** AAA AE DH QS JS MN PL DN KA MY.**Formal analysis:** AAA AE DH QS KA MY.**Funding acquisition:** AAA DH QS PL DN KA MY.**Investigation:** AAA AE DH QS JS MN PL DN KA MY.**Methodology:** AAA AE DH QS KA MY.**Project administration:** AAA AE DH QS JS MN PL DN KA MY.**Resources:** QS DH.**Software:** AAA AE DH QS KA MY.**Supervision:** AAA DH QS DN KA MY.**Validation:** AAA AE DH QS DN KA MY.**Visualization:** AAA AE DH QS JS MN PL DN KA MY.**Writing -- original draft:** AA DH KA MY.**Writing -- review & editing:** AAA AE DH QS JS MN PL DN KA MY.

[^3]: ‡ These authors also contributed equally to this work.
